Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Common Equity: 2010-2025

Historic Common Equity for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $503.4 million.

  • Arrowhead Pharmaceuticals' Common Equity rose 163.48% to $503.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.4 million, marking a year-over-year increase of 163.48%. This contributed to the annual value of $503.4 million for FY2025, which is 163.48% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Common Equity stood at $503.4 million for FY2025, which was up 163.48% from $191.1 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Common Equity ranged from a high of $503.4 million in FY2025 and a low of $191.1 million during FY2024.
  • For the 3-year period, Arrowhead Pharmaceuticals' Common Equity averaged around $327.2 million, with its median value being $287.2 million (2023).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Common Equity crashed by 33.47% in 2024 and then surged by 163.48% in 2025.
  • Arrowhead Pharmaceuticals' Common Equity (Yearly) stood at $408.8 million in 2021, then grew by 2.33% to $418.3 million in 2022, then crashed by 31.36% to $287.2 million in 2023, then tumbled by 33.47% to $191.1 million in 2024, then soared by 163.48% to $503.4 million in 2025.